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REPORT
Large Intragenic Deletion in DSTYK Underlies
Autosomal-Recessive Complicated
Spastic Paraparesis, SPG23
John Y.W. Lee,1 Chao-Kai Hsu,2,3,25 Magdalene Michael,4,25 Arti Nanda,5,25 Lu Liu,6
James R. McMillan,6 Celine Pourreyron,7 Takuya Takeichi,1,8 Jakub Tolar,9,10 Evan Reid,11,12
Thomas Hayday,4 Sergiu C. Blumen,13,14 Saif Abu-Mouch,15 Rachel Straussberg,16,17
Lina Basel-Vanagaite,17,18,19,20 Yael Barhum,21,22 Yasmin Zouabi,16 Hejab Al-Ajmi,5 Hsin-Yu Huang,2
Ting-Chien Lin,2 Masashi Akiyama,8 Julia Y.Y. Lee,2 W.H. Irwin McLean,23 Michael A. Simpson,24
Maddy Parsons,4 and John A. McGrath1,23,*
SPG23 is an autosomal-recessive neurodegenerative subtype of lower limb spastic paraparesis with additional diffuse skin and hair dys-
pigmentation at birth followed by further patchy pigment loss during childhood. Previously, genome-wide linkage in an Arab-Israeli
pedigree mapped the gene to an approximately 25 cM locus on chromosome 1q24–q32. By using whole-exome sequencing in a further
Palestinian-Jordanian SPG23 pedigree, we identified a complex homozygous 4-kb deletion/20-bp insertion in DSTYK (dual serine-thre-
onine and tyrosine protein kinase) in all four affected family members. DSTYK is located within the established linkage region and we
also found the same mutation in the previously reported pedigree and another Israeli pedigree (total of ten affected individuals from
three different families). The mutation removes the last two exons and part of the 30 UTR of DSTYK. Skin biopsies revealed reduced
DSTYK protein levels along with focal loss of melanocytes. Ultrastructurally, swollen mitochondria and cytoplasmic vacuoles were
also noted in remaining melanocytes and some keratinocytes and fibroblasts. Cultured keratinocytes and fibroblasts from an affected
individual, as well as knockdown ofDstyk inmousemelanocytes, keratinocytes, and fibroblasts, were associatedwith increased cell death
after ultraviolet irradiation. Keratinocytes from an affected individual showed loss of kinase activity upon stimulation with fibroblast
growth factor. Previously, dominant mutations in DSTYK were implicated in congenital urological developmental disorders, but our
study identifies different phenotypic consequences for a recurrent autosomal-recessive deletion mutation in revealing the genetic basis
of SPG23.
The hereditary spastic paraplegias (HSPs) are a group of in-
herited disorders characterized by spastic paralysis of the
lower limbs. The genetic basis of HSPs is complex, with
more than 70 subtypes.1 Among these, spastic paraplegia
type 23 (SPG23 [MIM: 270750]) is a rare subtype present-
ing in childhood with progressive spastic paraplegia associ-
ated with peripheral neuropathy, skin pigment abnormal-
ities (i.e., vitiligo, hyperpigmentation, diffuse lentigines),
and premature graying of hair. To date, only five reports
have been documented (Table S1).2–6 The affected individ-
uals in three of these reports were from the Middle East
(two Arab-Israeli and one Jordanian),2–4 another individual
was of North European descent,5 and the most recent case
was from India.6 In the Arab-Israeli family originally re-
ported in 1985,4 linkage analysis mapped the causative
gene to a 25-cM region on chromosome 1q24–q32
(maximum LOD score of 3.05).7 This interval contained
approximately 276 genes but no candidate gene and path-
ogenic mutations were identified.
To identify mutations that cause SPG23, we investigated
an additional, previously unreported, Kuwaiti-Jordanian
family (family 1) containing four affected individuals with
evidence of autosomal-recessive inheritance (Figure 1A).
The proband, a 22-year-old male Palestinian (individual
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IV-5), presented with life-long silvery-gray hair on the
scalp, eyebrows (Figure 1B), and eyelashes; his beard area
(Figure 1C) and secondary sexual hair were also affected
by focal pigment loss after puberty. In addition, during
childhood he had patchy pigmentary changes on his skin,
with later onset (early 20s) of more depigmented, vitiligo-
like lesions on the lips, hands, and forearms (Figures 1D
and 1E). He developed a waddling gait from the age of 2–3
years with subsequent emergence of spastic paraplegia
requiring wheelchair use from the age of 9 years. He is of
normal intelligence, and there is no history of epilepsy,
sensorineural deafness, or other motor or sensory neuro-
logic manifestations. He is the third of six living siblings
from a parent-related (first cousin) family, and his younger
brother (IV-8) and two female cousins (VI-1 and VI-2) have
similar phenotypes. His bladder function is normal but he
and his younger brother both experience bowel urgency
and incontinence. The younger brother also experienced
convulsions at the age of 6 years after a high-grade fever.
In the proband (IV-5), laboratory tests (full blood count
and serumbiochemistry)were all unremarkable. Brainmag-
netic resonance imaging showed no gross abnormalities.
An X-ray of his hips showed bilateral dislocation. Ultra-
sound of his abdomen and pelvis revealed a horseshoe kid-
neymalformation, although no urogenital anomalies were
detected in his affected brother (IV-8); screening has not yet
been undertaken in either of the two other affected family
members.
Figure 1. Pedigree and Molecular Pathology of SPG23
(A) The family pedigree of family 1. Squares denote male family members and circles female family members; filled-in symbols indicate
clinically affected individuals. The triangle (IV-2) refers to a spontaneous abortion.
(B) Affected individual IV-5 with gray/white hair in the scalp and eyebrows and dyspigmentation on the forehead.
(C) Similar changes affecting hair follicle pigmentation are present in the beard area (individual IV-5).
(D) Blotchy dyspigmentation, hypopigmentation, and depigmentation on the dorsum of the hands withmarked pigment loss and some
erythema around the finger nails.
(E) Loss of skin pigment (vitiligo-like lesions) on the flexural aspects of the wrists and forearms (individual IV-5).
(F) Integrative Genomics Viewer analysis reveals homozygous loss of exons 12 and 13 and part of the 30 UTR of DSTYK in affected in-
dividuals IV-5, IV-8, VI-1, and VI-2. Heterozygous changes are implicated in the parental samples (III-3, III-4, V-1, and V-2).
(G) Schematic ofDSTYK to show the homozygousmutation and Sanger sequencing confirmation of the 4-kb deletion/20-bp insertion in
genomic DNA (affected individual IV-5). The schematic also illustrates the previous mutations in DSTYK identified in a different disor-
der, autosomal-dominant congenital anomalies of the kidney and urinary tract-1 (CAKUT1).
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To identify the underlying molecular genetic defect in
these individuals, we obtained blood for genetic testing
and skin samples (ellipse of skin taken under local anes-
thesia by 1% lignocaine) from members of this family in
adherence to the Declaration of Helsinki. Whole-exome
sequencing was performed using genomic DNA extracted
from peripheral blood from all affected individuals and
their respective parents. Whole-exome capture was per-
formed on these eight samples using in-solution hybridiza-
tion (Agilent All Exon V4) and sequence data were gener-
ated on the Illumina HiSeq 2000. The reads produced
were aligned to the reference human genome using the
NovoAlign software package (Novocraft Technologies Sdn
Bhd). Duplicate reads, arising from PCR clonality or optical
duplicates, and reads mapping to multiple regions were
removed from downstream analysis. A summary of exome
coverage data is presented in Table S2.
Whole-exome sequencing failed to reveal any rare, path-
ogenic homozygous single-nucleotide variants or indels
that were present in all four affected individuals. However,
we observed two blocks of homozygosity that were shared
among all four affected individuals, namely a 9.9-Mb block
at chromosome 1q32 and a 4.4-Mb block at chromosome
9p13. Because the SPG23 locus had previously been map-
ped to chromosome 1q24–q32,7 we analyzed copy-num-
ber variation (CNV) data with the ExomeDepth software
package8 and identified a putative homozygous intragenic
deletion in DSTYK in each of the affected individuals,
which completely removed the last two exons (12 and
13) along with part of the 30 UTR (Figure 1F). Using a
‘‘primer walk’’ approach, the precise breakpoints of the
deletion in intron 11 and the 30 UTR were identified
(Figure 1G), with coordinates from chromosome 1:
205,145,663–205,149,750 (GRCh38/hg38 assembly). This
mutation was absent from an in-house exome bank
and public databases, including DECIPHER,9 Database of
Genomic Variants,10 and Copy Number Variation in Dis-
ease.11 Intriguingly, this 4-kb deletion was accompanied
by the insertion of an intervening 20-bp sequence. Using
the Basic Local Alignment Search Tool (BLAST), this
sequence was shown to originate from 5,765 bp down-
stream of the original stop codon (chr1: 205,141,774–
205,141,793) and inverted prior to re-insertion. Addition-
ally, all affected individuals carried the common SNP
rs3902193. Complex CNVs similar to the mutation identi-
fied here have previously been reported to be associated
with human genetic disease.12,13 We then assessed correla-
tion of the mutation with disease status in the rest of the
family by designing two further pairs of allele-specific
primers to selectively amplify the wild-type and mutant
alleles (Table S3) and confirmed that this deletion in
DSTYK fully segregates with phenotype (Figure S1).
Next, we investigated whether the previously reported
Arab-Israeli pedigree (family 2) linked to 1q24–q327 and
another unreported Israeli family (family 3) with an
SPG23 phenotype also carried a recessive mutation in
DSTYK. We found that the affected individuals in these
two families also carried the same intragenic deletion,
and this mutation also segregated with phenotype in the
rest of the family (Figures S2 and S3). Because all three ped-
igrees originated from the Middle East, we explored the
possibility that the deletion in DSTYK may represent a
founder mutation and that these families may be distantly
related. Using a number of microsatellite markers around
the DSTYK locus (Figure S4), we found that the three fam-
ilies had a shared haplotype around themutation, but with
a refined area of linkage of approximately 9.6 cM between
D1S413 and D1S2692. DSTYK is included within the new
interval (along with 202 other genes).
DSTYK, also known as Dusty protein kinase, receptor
interacting protein 5 (RIP5), or RIP kinase 5 (RIPK5), en-
codes dual serine-threonine and tyrosine protein kinase,
an enzyme implicated as a regulator of cell death.14 DSTYK
was found to induce both caspase-dependent and caspase-
independent cell death in a dose-dependent manner,14
although subsequent studies have challenged the notion
that DSTYK is a RIP5 family member.15,16 DSTYK mRNA
is expressed in multiple tissues, although normalized
expression distribution is highest in the spinal cord, pineal
gland, and skin according to the SOURCE database.17With
regard to human disease, heterozygous mutations in
DSTYK were identified as a frequent cause of autosomal-
dominant congenital anomalies of the kidney and urinary
tract-1 (CAKUT1 [MIM: 610805]).18 Notably, DSTYKmuta-
tions were found in 2.3% of CAKUT1-affected case sub-
jects, suggesting that DSTYK is a major determinant of hu-
man urinary tract development.18 Interestingly, among
individuals with these autosomal-dominant DSTYK muta-
tions, three family members with a splice site mutation
had epilepsy and an unrelated individual with a nonsense
mutation experienced early-onset ataxia. Nevertheless,
no skin or pigmentary changes were associated with these
heterozygous mutations.18
Next, we assessed DSTYK pathology in skin, after written
and informed consent according to a protocol approved by
the St Thomas’ Hospital Ethics Committee (Molecular basis
of inherited skin disease: 07/H0802/104). Peri-lesional skin
biopsies were obtained from the leg of affected individual
IV-5 of family 1 and assessed by immunofluorescence and
transmissionelectronmicroscopy (seeTable S5 for antibody
details). Immunofluorescence microscopy of DSTYK using
both N-terminal and C-terminal antibodies showed mark-
edly reduced labeling (Figures 2A and 2B) in the IV-5 skin
compared to control subjects. Transmission electronmicro-
scopy revealed focal loss of melanocytes with some of
the remaining melanocytes showing ultrastructural fea-
tures of swollen mitochondria and cytoplasmic vacuoles
(Figure 2C), but these abnormalities were not present in
apparently unaffected melanocytes in the same affected
individual (Figure S8). These enlarged mitochondria with
abnormal cristae were also observed in other cell types
such as fibroblasts and keratinocytes (Figure 2D). These
pathological findings indicate an increased susceptibility
of mutant cells to stress and cell death.
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To further explore the potential role for DSTYK in regu-
lating cell death, primary fibroblasts and keratinocytes
from this affected individual were isolated for further anal-
ysis, with the keratinocytes immortalized at passage 1. We
also generated Dstyk siRNA knockdown mouse fibroblasts,
keratinocytes, and melanocytes to determine whether
siRNA-depleted cells and cells from affected individuals ex-
hibited similar phenotypes. We first assessed whether loss
of DSTYK resulted in increased cell death. Cells were
exposed to a UV illuminator for 2 min and fixed after
9 hr and apoptosis levels were determined by analysis of
total cell number as a readout for cell death. For all cell
types, both Dstyk knockdown and mutant cells exhibited
increased cell death 9 hr after exposure to UV as shown
by loss of cell attachment (Figures 3A–3E). There were no
differences in cell death between Dstyk-depleted and con-
trol cells under basal conditions (data not shown). As alter-
native readouts for UV-induced apoptosis, cleaved caspase-
3 staining was also assessed and apoptotic markers were
analyzed by FACS analysis after UV treatment. A signifi-
cant increase in cells positive for cleaved caspase-3 staining
was observed in DSTYK-depleted keratinocytes and mela-
nocytes after 9 hr of UV exposure (Figures S5A–S5C);
Figure 2. Skin Pathology in SPG23
(A) Immunofluorescence microscopy using
a DSTYK N-terminal antibody (NBP1-
92336, 1:500, Novus Biologicals) in normal
skin (top) reveals bright pan-epidermal cyto-
plasmic staining with focal accentuation in
basal epidermal melanocytes and dermal fi-
broblasts. In affected individual (IV-5) skin
(middle), there is markedly reduced label-
ing, with an absence of staining in the nega-
tive control (bottom) (scale bar represents
100 mm).
(B) Immunofluorescence microscopy using
a DSTYK C-terminal antibody (1:500, Santa
Cruz Biotechnology cat# sc-374487, RRID:
AB_10988978) in normal skin (top) reveals
bright pan-epidermal cytoplasmic staining
with focal accentuation in basal epidermal
melanocytes and dermal fibroblasts. In
affected individual (IV-5) skin (middle)
there is markedly reduced labeling, with an
absence of staining in the negative control
(bottom).
(C) Transmission electron micrograph of a
melanocyte (affected individual IV-5) shows
prominent mitochondria and abnormal
cytoplasmic vacuoles (asterisk) (scale bar
represents 2 mm).
(D) Transmission electron micrograph of
a keratinocyte (affected individual IV-5)
shows prominent swollen mitochondria
with abnormal cristae (asterisks) (scale bar
represents 2 mm).
FACS analysis also revealed an increase
in Annexin V and 7-AAD labeling
in mutant fibroblasts compared to
controls, reflecting an increase in
both early and late apoptotic markers
(Figure S5D), which confirmed the increased susceptibility
to apoptotic signaling due to the loss of DSTYK protein. To
assess whether loss of DSTYK altered mitochondrial archi-
tecture, we stained live knockdown and mutant cells with
MitoTracker Red followed by fixation and analysis by
confocal microscopy. All cell types showed dispersed and
enlarged mitochondrial organization in response to UV,
but no marked changes in this response were observed in
Dstyk knockdown or mutant cells compared to control
cells (Figures S6A–S6C and data not shown). DSTYK has
previously been shown to be a positive regulator of extra-
cellular signal-regulated kinase (ERK) phosphorylation
downstream of FGF stimulation in HEK293T cells.18 We
therefore determined whether cells from affected individ-
uals showed loss of pERK activity upon FGF stimulation.
Biochemical analysis demonstrated that primary mutant
keratinocytes showed significantly reduced pERK activa-
tion in response to FGF stimulation compared to control
cells (Figures S7A and S7B), confirming previous observa-
tions on the role of DSTYK in regulating FGF signaling.
Our study indicates that the molecular basis of SPG23,
at least in three pedigrees, involves a large 30 deletion in
DSTYK, and thus two specific disease entities, SPG23 and
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CAKUT1, harbor mutations in the same gene. Aside from
the different mode of inheritance, the heterozygous muta-
tions in CAKUT1 have been mostly upstream of the kinase
domain, with the exception of one missense mutation in
exon 12.18 In contrast, the intragenic deletion we identi-
fied occurs near the C terminus and appears to lead to
reduction of protein levels. Nevertheless, a minor overlap
in phenotype occurs—with the SPG23 proband in our
study also having a structural renal anomaly, and some
neurologic features being described in CAKUT1. Overall,
the lack of urinary tract abnormalities in heterozygotes
and some homozygotes in the three SPG23 pedigrees pre-
sented in our study indicates that this novel deletion has
a distinct functional impact. Morpholino knockdown of
dstyk in zebrafish was shown to result in a wide spectrum
of defects including growth retardation, abnormal tail
morphogenesis, loss of heartbeat, cloacal malformations,
and abnormalities in jaw development.18 Dstyk kinase
domain-knockout mice showed impaired learning and
memory capabilities but had no significant morphological
defects.19 The apparent discrepancy between the features
seen in mutant mice with CAKUT1 and SPG23 cases may
be due to the fact that full-length DSTYK was not ablated
in these mice and a truncated protein may still have
Figure 3. Increased Sensitivity to Apoptosis in DSTYK-Null Cells
(A) Western blots of DSTYK protein levels in mouse NIH 3T3 fibroblasts transfected with non-targeting siRNA (control) or siRNA pool
specifically targeted to Dstyk (Dstyksi). Graph shows percentage of total starting cells attached 9 hr after UV illumination. Values are
means5 standard error of the mean (SEM). Representative of three independent experiments. *p < 0.05.
(B) Western blots of DSTYK protein levels in human fibroblasts isolated from healthy donors (control) or affected individual (IV-5).
Graph shows percentage of total starting cells attached 9 hr after UV illumination. Values are means 5 SEM. Representative of three
independent experiments. *p < 0.05.
(C) Western blots of DSTYK protein levels in mouse keratinocytes transfected with non-targeting siRNA (control) or siRNA pool specif-
ically targeted to Dstyk (Dstyksi). Graph shows percentage of total starting cells attached 9 hr after UV illumination. Values are means5
SEM. Representative of three independent experiments. *p < 0.05.
(D) Western blots of DSTYK protein levels in human keratinocytes isolated from healthy donors (control) or affected individual (IV-5).
Graph shows percentage of total starting cells attached 9 hr after UV illumination. Values are means 5 SEM. Representative of three
independent experiments. *p < 0.05.
(E) Western blots of DSTYK protein levels in mouse melanocytes transfected with non-targeting siRNA (control) or siRNA pool specif-
ically targeted to Dstyk (Dstyksi). Graph shows percentage of total starting cells attached 9 hr after UV illumination. Values are
means5 SEM. Representative of three independent experiments. *p < 0.05.
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been present.19 Moreover, our data suggest that DSTYK
acts to suppress apoptosis in response to UV-induced
stress, the response to which remains unknown in animal
models of DSTYK dysfunction.
Our data suggest that loss of DSTYK in fibroblasts, kera-
tinocytes, and melanocytes leads to increased susceptibil-
ity to apoptosis (quantified by cell number, cleaved cas-
pase-3 staining, and FACS analysis). Various modalities of
cell death can occur, including necrosis, necroptosis, and
pyroptosis,20 and mitochondrial swelling has also been
associated with non-apoptotic forms of programmed cell
death.21 DSTYK has previously been proposed to be a pos-
itive regulator of both caspase-dependent and -indepen-
dent cell death pathways.14 However, this was shown to
occur only after overexpression of DSTYK in HEK293 cells
and in the absence of external stress stimuli. Our data show
that in the context of skin, DSTYK plays a predominant
role in suppressing caspase-dependent apoptosis in
response to UV stress in a range of dermal cell types. Future
studies will focus on understanding the mechanisms by
which DSTYK contributes to apoptosis protection.
One pertinent clinical feature in the skin in individuals
with SPG23 is loss of skin pigment: some of this pathology
may reflect post-inflammatory hypopigmentation but
certain lesions show complete depigmentation in keeping
with vitiligo, a common complex disorder associated with
autoimmune destruction of melanocytes in skin and
hair. Other cases of vitiligo may show familial clustering
although inheritance is non-Mendelian and multi-facto-
rial.22 To date, approximately 40 loci with convincing or
strongly suggestive evidence for a role in vitiligo suscepti-
bility have been identified,23 although there has been no
association with DSTYK or its locus on 1q32.1, indicating
that DSTYK may not be involved in common complex
versions of this condition. The vitiligo in our cases likely
reflects localized cell killing of melanocytes, although
how the deletion in DSTYK preferentially leads to melano-
cyte loss is uncertain, particularly given the presence of
abnormal vacuoles and swollen mitochondria in several
skin cell types, including melanocytes, keratinocytes, and
fibroblasts. Both melanocytes and Schwann cells are
derived from the neural crest, and these two distinct cell
types have been proposed to originate from a common
post-neural crest progenitor, namely the Schwann cell pre-
cursor.24 The motor and pigmentary symptoms in individ-
uals with SPG23 may be a manifestation of increased
vulnerability of Schwann cell precursors to cell death,
but further studies in appropriate model systems are
needed to dissect the underlying pathomechanisms of
this unique disorder.
In summary, we have identified a large intragenic
deletion in DSTYK as the molecular basis for three fam-
ilies with SPG23, an autosomal-recessive disorder charac-
terized by spastic paraparesis and dyspigmentation.
Our data in skin tissue also indicate the clinical conse-
quences of abnormal cell death, highlighting findings of
potential relevance to other more common disease pro-
cesses in the skin, such as vitiligo and other dyspigmen-
tary dermatoses.
Supplemental Data
Supplemental Data include eight figures and five tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
2017.01.014.
Acknowledgments
The Centre for Dermatology andGeneticMedicine is supported by
a Wellcome Trust Strategic Award (reference 098439/Z/12/Z). The
work was supported by the MRC (MR/M018512/1) and the UK
National Institute for Health Research (NIHR) comprehensive
Biomedical Research Centre (BRC) award to Guy’s and St. Thomas’
NHS Foundation Trust, in partnership with the King’s College
London and King’s College Hospital NHS Foundation Trust. This
study was also supported by UK Medical Research Council Project
Grant (MR/M00046X/1) and Action Research grant SP3706 as well
as medical student grants from the Jean Shanks Foundation and
the British Association of Dermatologists. We thank Akemi Ish-
ida-Yamamoto (Asahikawa, Japan) for help with transmission elec-
tron microscopy analysis.
Received: September 11, 2016
Accepted: January 5, 2017
Published: February 2, 2017
Web Resources
BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi
CNVD, http://202.97.205.78/CNVD/index.jsp
Database of Genomic Variants (DGV), http://dgv.tcag.ca/dgv/app/
home
DECIPHER, http://decipher.sanger.ac.uk/
Ensembl Genome Browser, http://www.ensembl.org/index.html
OMIM, http://www.omim.org/
Primer3, http://bioinfo.ut.ee/primer3
PubMed, http://www.ncbi.nlm.nih.gov/PubMed/
RefSeq, http://www.ncbi.nlm.nih.gov/RefSeq
References
1. Hensiek, A., Kirker, S., and Reid, E. (2015). Diagnosis, investi-
gation and management of hereditary spastic paraplegias in
the era of next-generation sequencing. J. Neurol. 262, 1601–
1612.
2. Abdallat, A., Davis, S.M., Farrage, J., and McDonald, W.I.
(1980). Disordered pigmentation, spastic paraparesis and pe-
ripheral neuropathy in three siblings: a new neurocutaneous
syndrome. J. Neurol. Neurosurg. Psychiatry 43, 962–966.
3. Lison, M., Kornbrut, B., Feinstein, A., Hiss, Y., Boichis, H., and
Goodman, R.M. (1981). Progressive spastic paraparesis, viti-
ligo, premature graying, and distinct facial appearance: a
new genetic syndrome in 3 sibs. Am. J. Med. Genet. 9,
351–357.
4. Mukamel, M., Weitz, R., Metzker, A., and Varsano, I. (1985).
Spastic paraparesis, mental retardation, and cutaneous
pigmentation disorder. A new syndrome. Am. J. Dis. Child.
139, 1090–1092.
The American Journal of Human Genetics 100, 364–370, February 2, 2017 369
5. Bamforth, J.S. (2003). Vitiligo-spasticity syndrome: new case.
Clin. Dysmorphol. 12, 137–139.
6. Mandal, S., and Bid, D. (2009). Vitiligo with spastic parapare-
sis: A rare neurocutaneous syndrome. J. Pediatr. Neurol. 7,
329–331.
7. Blumen, S.C., Bevan, S., Abu-Mouch, S., Negus, D., Kahana,
M., Inzelberg, R., Mazarib, A., Mahamid, A., Carasso, R.L.,
Slor, H., et al. (2003). A locus for complicated hereditary spas-
tic paraplegia maps to chromosome 1q24-q32. Ann. Neurol.
54, 796–803.
8. Plagnol, V., Curtis, J., Epstein, M., Mok, K.Y., Stebbings, E.,
Grigoriadou, S., Wood, N.W., Hambleton, S., Burns, S.O.,
Thrasher, A.J., et al. (2012). A robust model for read count
data in exome sequencing experiments and implications
for copy number variant calling. Bioinformatics 28, 2747–
2754.
9. Firth, H.V., Richards, S.M., Bevan, A.P., Clayton, S., Corpas, M.,
Rajan, D., Van Vooren, S., Moreau, Y., Pettett, R.M., and Carter,
N.P. (2009). DECIPHER: Database of Chromosomal Imbalance
and Phenotype in Humans Using Ensembl Resources. Am. J.
Hum. Genet. 84, 524–533.
10. MacDonald, J.R., Ziman, R., Yuen, R.K., Feuk, L., and Scherer,
S.W. (2014). The Database of Genomic Variants: a curated
collection of structural variation in the human genome.
Nucleic Acids Res. 42, D986–D992.
11. Qiu, F., Xu, Y., Li, K., Li, Z., Liu, Y., DuanMu, H., Zhang, S., Li,
Z., Chang, Z., Zhou, Y., et al. (2012). CNVD: textmining-based
copy number variation in disease database. Hum. Mutat. 33,
E2375–E2381.
12. Chen, J.M., Chuzhanova, N., Stenson, P.D., Fe´rec, C., and
Cooper, D.N. (2005). Intrachromosomal serial replication slip-
page in trans gives rise to diverse genomic rearrangements
involving inversions. Hum. Mutat. 26, 362–373.
13. Sheen, C.R., Jewell, U.R., Morris, C.M., Brennan, S.O., Fe´rec,
C., George, P.M., Smith, M.P., and Chen, J.M. (2007). Double
complex mutations involving F8 and FUNDC2 caused by
distinct break-induced replication. Hum. Mutat. 28, 1198–
1206.
14. Zha, J., Zhou, Q., Xu, L.G., Chen, D., Li, L., Zhai, Z., and Shu,
H.B. (2004). RIP5 is a RIP-homologous inducer of cell death.
Biochem. Biophys. Res. Commun. 319, 298–303.
15. Meylan, E., and Tschopp, J. (2005). The RIP kinases: crucial in-
tegrators of cellular stress. Trends Biochem. Sci. 30, 151–159.
16. Peng, J., Dong, W., Chen, Y., Mo, R., Cheng, J.F., Hui, C.C.,
Mohandas, N., and Huang, C.H. (2006). Dusty protein
kinases: primary structure, gene evolution, tissue specific
expression and unique features of the catalytic domain. Bio-
chim. Biophys. Acta 1759, 562–572.
17. Diehn, M., Sherlock, G., Binkley, G., Jin, H., Matese, J.C., Her-
nandez-Boussard, T., Rees, C.A., Cherry, J.M., Botstein, D.,
Brown, P.O., and Alizadeh, A.A. (2003). SOURCE: a unified
genomic resource of functional annotations, ontologies, and
gene expression data. Nucleic Acids Res. 31, 219–223.
18. Sanna-Cherchi, S., Sampogna, R.V., Papeta, N., Burgess, K.E.,
Nees, S.N., Perry, B.J., Choi, M., Bodria, M., Liu, Y., Weng,
P.L., et al. (2013). Mutations in DSTYK and dominant urinary
tract malformations. N. Engl. J. Med. 369, 621–629.
19. Li, K., Liu, J.W., Zhu, Z.C., Wang, H.T., Zu, Y., Liu, Y.J., Yang,
Y.H., Xiong, Z.Q., Shen, X., Chen, R., et al. (2014). DSTYK
kinase domain ablation impaired the mice capabilities of
learning and memory in water maze test. Int. J. Clin. Exp.
Pathol. 7, 6486–6492.
20. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J.,
Alnemri, E.S., Baehrecke, E.H., Blagosklonny, M.V., El-Deiry,
W.S., Golstein, P., Green, D.R., et al.; Nomenclature Commit-
tee on Cell Death 2009 (2009). Classification of cell death:
recommendations of the Nomenclature Committee on Cell
Death 2009. Cell Death Differ. 16, 3–11.
21. Sperandio, S., de Belle, I., and Bredesen, D.E. (2000). An alter-
native, nonapoptotic form of programmed cell death. Proc.
Natl. Acad. Sci. USA 97, 14376–14381.
22. Spritz, R.A. (2013). Modern vitiligo genetics sheds new light
on an ancient disease. J. Dermatol. 40, 310–318.
23. Shen, C., Gao, J., Sheng, Y., Dou, J., Zhou, F., Zheng, X., Ko, R.,
Tang, X., Zhu, C., Yin, X., et al. (2016). Genetic susceptibility
to vitiligo: GWAS approaches for identifying vitiligo suscepti-
bility genes and loci. Front. Genet. 7, 3.
24. Adameyko, I., Lallemend, F., Aquino, J.B., Pereira, J.A.,
Topilko, P., Mu¨ller, T., Fritz, N., Beljajeva, A., Mochii, M., Liste,
I., et al. (2009). Schwann cell precursors from nerve innerva-
tion are a cellular origin of melanocytes in skin. Cell 139,
366–379.
370 The American Journal of Human Genetics 100, 364–370, February 2, 2017
